NCT05210803
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Enrolling by Invitation
Not specifiedAll AgesObservationalAbbVie
~115 participants
Updated 2025-06-18 on ClinicalTrials.gov
What's tested:No intervention.
At a glance
Recruiting sites
0 of 16 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the long-term safety of RGX-314
Measured over 5 years inclusive of parent study
Conditions
Where it's being run
16 sites across 11 statesCalifornia5
Tennessee2
Arizona1
Georgia1
Maryland1
Massachusetts1
Minnesota1
Nevada1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- To evaluate the long-term safety of RGX-3145 years inclusive of parent study
Incidences of ocular Adverse Events and Serious Adverse Events, and all Adverse Events of Special Interest